Back to Balyasny Asset Management L.P. Balyasny Asset Management L.P.

XLOXLO

Showing 6 of 8 quarters

Position history for Balyasny Asset Management L.P.Balyasny Asset Management L.P.'s holdings in Xilio Therapeutics, Inc.

No. Balyasny Asset Management exited its XLO (Xilio Therapeutics) position in Q4 2025. Its Q3 2025 13F listed 198,859 shares worth $167,578. Balyasny Asset Management first reported XLO in Q1 2024 and held it in 7 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$214,637

Total Shares Change

-272,486

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q4
Latest
Exited
0
-100.0%
$00.0%$8.96
0
2025-Q3
Unchanged
198,859
0.0%
$167,5780.0%$11.80
0
2025-Q2
Decreased
198,859
-21.8%
$135,2040.0%$9.52
0
2025-Q1
Decreased
254,346
-25.9%
$184,2480.0%$10.14
0
2024-Q4
Increased
343,230
+26.0%
$327,7850.0%$13.37
29
2024-Q3
Unchanged
272,486
0.0%
$214,6370.0%$11.03
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used